Skip to main content

Table 1 US FDA approved PD-1/PD-L1 inhibitors

From: Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway

TargetMoleculeApproved indicationsCompanyCommercial name
PD-1Nivolumab (BMS-936558, MDX1106, ONO4538)CRC (MSI high), HNSCC, HCC, Hodgkin lymphoma, melanoma, NSCLC, RCC, SCLC, UCBristol-Meyers Squibb/OnoOpdivo
Pembrolizumab (MK-3475, Lambrolizumab)Cervical cancer, CRC, endometrial cancer, esophageal cancer, gastric cancer, HNSCC, HCC, Hodgkin lymphoma, melanoma, Merkel cell carcinoma, MSI high cancer, NSCLC, PMBCL, RCC, SCLC, UCMerckKeytruda
CemiplimabCutaneous squamous cell carcinomaSanofiLibtayo
PD-L1Atezolizumab (MPDL3280A)Breast cancer, NSCLC, SCLC, UCRoche/GenentechTecentriq
Durvalumab (MEDI4736)NSCLC, UCMedImmune/AstraZeneca/ CelgeneImfinzi
Avelumab (MSB0010718C)Merkel cell carcinoma, RCC, UCMerck Serono/PfizerBavencio
  1. CRC Colorectal cancer, HCC Hepatocellular carcinoma, HNSCC Head and neck squamous cell carcinoma, MSI Microsatellite instability, NSCLC Non-small cell lung cancer, PMBCL Primary mediastinal large B cell lymphoma, RCC Renal cell carcinoma, SCLC Small cell lung cancer, UC Urothelial carcinoma